Ondansetron dosage
Ondansetron doses are not one-size-fits-all: the FDA label prescribes 24 mg for highly emetogenic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy, and 16 mg before anesthesia. The single most consequential number on the label is not a dose at all but a ceiling: in severe hepatic impairment, total daily intake must not exceed 8 mg. Two other facts get overlooked. The current label carries no 32 mg single intravenous dose, and ondansetron does nothing for motion sickness because motion sickness is a vestibular problem and ondansetron does not act on that pathway. Every figure below is quoted from the current FDA prescribing information.
This is reference, not a dosing instruction. Ondansetronis prescription-only and the dose is individualized and titrated by a prescriber to your condition, response, kidney/liver function and other medicines. The figures below are the FDA label’s — do not start, change or stop a dose based on this page.
Approved for: Ondansetron is a 5-HT3 receptor antagonist approved only for preventing nausea and vomiting from four specific triggers: highly emetogenic cancer chemotherapy (including cisplatin at or above 50 mg/m2), initial and repeat courses of moderately emetogenic chemotherapy, radiotherapy in patients receiving total body irradiation or single high-dose or daily fractions to the abdomen, and postoperative nausea and/or vomiting. Note what is absent from that list: motion sickness, morning sickness, and general stomach flu are not FDA-approved uses.
Available as: Tablets: Zofran-brand strengths are 4 mg (white) and 8 mg (yellow); the 24 mg strength used for the highly emetogenic chemotherapy dose is a generic ondansetron tablet. orally disintegrating tablets (ODT) 4 mg and 8 mg; oral solution 4 mg/5 mL. Zofran tablets are oval and film-coated, engraved 'Zofran' on one side with '4' or '8' on the other; ODT tablets are white, round, debossed 'Z4' or 'Z8'. An injectable form also exists for hospital use. Tablets, ODT, and oral solution doses may be used interchangeably.
| Use | What the label says |
|---|---|
| Highly emetogenic chemotherapy (adults, oral) | The label specifies "A single 24-mg dose administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin greater than or equal to 50 mg/m2." This is the only indication that uses the 24 mg tablet, and it is a one-time dose, not a repeating schedule. |
| Moderately emetogenic chemotherapy (adults, oral) | "8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8-mg dose 8 hours after the first dose. Then administer 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy." So: two doses on treatment day, then twice-daily for up to two days after. |
| Radiotherapy (adults, oral) | For total body irradiation: "8 mg administered 1 to 2 hours before each fraction of radiotherapy each day." For single high-dose fraction radiotherapy to the abdomen: "8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8-mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy." For daily fractionated radiotherapy to the abdomen: the same 8 mg pre-dose plus 8 mg every 8 hours for each day radiotherapy is given. |
| Post-operative nausea and vomiting (adults) | Oral: "16 mg administered 1 hour before induction of anesthesia" — a single dose, and the only indication using 16 mg orally. By injection the post-operative dose is far smaller: a single 4 mg IV dose over at least 30 seconds, given immediately before induction of anesthesia or afterward if nausea and vomiting appear within two hours of surgery. |
| Children (weight and age-based) | Oral, moderately emetogenic chemotherapy only. Ages 12 to 17: "8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8-mg dose 8 hours after the first dose," then 8 mg every 12 hours for 1 to 2 days. Ages 4 to 11: "4 mg administered 30 minutes before the start of chemotherapy, with a subsequent 4-mg dose 4 and 8 hours after the first dose," then "4 mg three times a day for 1 to 2 days." Intravenous post-operative dosing is weight-based for ages 1 month to 12 years: 4 mg for children over 40 kg, and 0.1 mg/kg for children 40 kg or less. |
| Intravenous chemotherapy dosing (adults and children 6 months and older) | "0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose)," infused over 15 minutes, with the first dose 30 minutes before chemotherapy and the next two at 4 and 8 hours after the first. |
Maximum dose
The largest per-dose figure anywhere on the IV label is the chemotherapy cap of 16 mg per dose — the label states no universal single-dose IV ceiling. The IV chemotherapy regimen is written as "0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose)." Orally, the largest labeled single dose is 24 mg, used once for highly emetogenic chemotherapy. The hardest ceiling applies to liver disease: in severe hepatic impairment the total daily dose must not exceed 8 mg by any route. There is no labeled as-needed maximum for general nausea, because general nausea is not an approved use.
Dose adjustments
Hepatic impairment is the one adjustment on the label, and it is severe: "In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), do not exceed a total daily dose of 8 mg." The injection label states the same limit: "A total daily dose of 8 mg should not be exceeded." This is because clearance falls and the apparent volume of distribution rises in severe liver disease, substantially lengthening ondansetron's half-life. That 8 mg per day cap is total across all doses and all forms — a single 24 mg chemotherapy tablet is three times the entire daily allowance for these patients. No dose adjustment is specified for kidney impairment or for age alone.
Dosing safety — read before you rely on any number
QT prolongation and torsades de pointes head the list. The label states that "Electrocardiogram (ECG) changes, including QT interval prolongation have been seen in patients receiving ondansetron. In addition, postmarketing cases of Torsade de Pointes have been reported." It directs prescribers to "Avoid ZOFRAN in patients with congenital long QT syndrome," and recommends ECG monitoring in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, congestive heart failure, bradyarrhythmias, or those taking other medicinal products that lead to QT prolongation. Serotonin syndrome is the second: it "has been reported with 5-HT3 receptor antagonists alone," though most reports involve concurrent serotonergic drugs including SSRIs, SNRIs, MAO inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue, and some reported cases were fatal. Ondansetron is contraindicated with apomorphine because of profound hypotension and loss of consciousness, and in anyone with hypersensitivity to it. The label also flags myocardial ischemia and warns that ondansetron can mask progressive ileus or gastric distension after abdominal surgery. Separately, and importantly: ondansetron is not a motion sickness drug. It blocks 5-HT3 receptors in the chemoreceptor trigger zone and on vagal afferents, which is a chemical and gut-driven pathway. Motion sickness originates in the vestibular system of the inner ear, which runs on histamine and acetylcholine — the targets of meclizine and scopolamine. Motion sickness is not among ondansetron's four FDA-approved indications, and taking it before a boat or a flight is a widespread and predictable disappointment.
Bottom line
Ondansetron's dose is set by what caused the nausea, not by how bad it feels: 24 mg once for highly emetogenic chemotherapy, 8 mg twice daily for moderately emetogenic, 8 mg before radiotherapy fractions, 16 mg orally before anesthesia. Children are dosed 8 mg (12-17 years) or 4 mg (4-11 years). Two hard limits matter more than the doses themselves — no single IV dose above 16 mg, because the 32 mg dose was removed from the label over QT prolongation and torsades risk, and no more than 8 mg total per day in severe hepatic impairment. Anyone with congenital long QT syndrome should avoid it, and anyone on SSRIs, SNRIs, or tramadol should know serotonin syndrome is possible. If you are looking for motion sickness relief, ondansetron is the wrong pharmacology; ask about meclizine or scopolamine instead.
Frequently asked questions
What is the ondansetron dosage for adults?
It depends entirely on the indication, and the FDA label gives four different answers. Highly emetogenic chemotherapy: a single 24 mg dose 30 minutes before treatment. Moderately emetogenic chemotherapy: 8 mg 30 minutes before, another 8 mg eight hours later, then 8 mg every 12 hours for one to two days afterward. Radiotherapy: 8 mg one to two hours before each fraction. Post-operative nausea: 16 mg orally one hour before induction of anesthesia, or 4 mg by IV. There is no labeled adult dose for ordinary stomach upset, because that is not an approved use.
How often can you take Zofran?
Frequency is written into each labeled regimen rather than left to the patient. For moderately emetogenic chemotherapy the label says 8 mg "twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy." For radiotherapy to the abdomen it is every 8 hours. For children 4 to 11 it is "4 mg three times a day for 1 to 2 days." The highly emetogenic chemotherapy 24 mg dose and the 16 mg pre-anesthesia dose are single doses, not repeated. If you have severe hepatic impairment, frequency is capped by the total: no more than 8 mg in a day, whatever the schedule.
Does Zofran work for motion sickness?
No, and the reason is mechanistic rather than a matter of dose. Ondansetron blocks 5-HT3 (serotonin) receptors in the chemoreceptor trigger zone and on vagal nerve endings in the gut — the pathway that chemotherapy, radiation, and anesthesia activate. Motion sickness arises in the vestibular apparatus of the inner ear, which signals through histamine and acetylcholine receptors that ondansetron does not touch. Motion sickness is not one of the four indications on the FDA label. The drugs built for that pathway are antihistamines such as meclizine and dimenhydrinate, or the anticholinergic scopolamine patch. Taking Zofran before a cruise is a common and understandable mistake, but it is aiming at the wrong receptor.
What is the Zofran dose for children?
The oral label covers children only for moderately emetogenic chemotherapy, split by age. Ages 12 to 17 get the adult regimen: 8 mg 30 minutes before chemotherapy, 8 mg eight hours later, then 8 mg every 12 hours for one to two days. Ages 4 to 11 get "4 mg administered 30 minutes before the start of chemotherapy, with a subsequent 4-mg dose 4 and 8 hours after the first dose," then 4 mg three times daily for one to two days. Intravenous post-operative dosing is by weight for ages 1 month to 12 years: 4 mg if over 40 kg, 0.1 mg/kg if 40 kg or under. IV chemotherapy dosing extends down to 6 months of age at 0.15 mg/kg per dose. Children under 4 have no labeled oral dose.
Can Zofran cause heart problems?
Yes, and the FDA has acted on it. The label reports ECG changes including QT interval prolongation, plus postmarketing cases of torsades de pointes, a dangerous ventricular arrhythmia. QT prolongation is dose-dependent. Label §12.2: "The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 19.5 (21.8) milliseconds and 5.6 (7.4) milliseconds after 15-minute intravenous infusions of 32 mg and 8 mg of ondansetron injection, respectively." The current label carries no 32 mg single IV dose; the highest per-dose figure on it is the 16 mg chemotherapy cap. The label instructs prescribers to avoid ondansetron in congenital long QT syndrome and to monitor ECGs in patients with hypokalemia or hypomagnesemia, congestive heart failure, bradyarrhythmias, or on other QT-prolonging drugs. Myocardial ischemia is also listed as a warning.
Zofran 4 mg vs 8 mg — what is the difference?
They serve different populations and different intensities of trigger. The 4 mg strength is the pediatric oral dose for ages 4 to 11 and the standard adult single IV dose for post-operative nausea. The 8 mg strength is the adult oral dose for moderately emetogenic chemotherapy and all radiotherapy indications, and the oral dose for ages 12 to 17. Neither is a general-purpose strength you choose by how nauseated you feel — the label assigns them by indication and age. One practical note: for a patient with severe hepatic impairment, 8 mg is the entire permitted daily dose, so a single 8 mg tablet exhausts the day's allowance while a 4 mg tablet leaves room for a second.
Sources
More guides for Ondansetron
Other dosage guides: Metformin dosage · Amoxicillin dosage · Prednisone dosage · Gabapentin dosage · Ibuprofen dosage · Lisinopril dosage · Levothyroxine dosage · Omeprazole dosage · Doxycycline dosage · Albuterol dosage · Allopurinol dosage · Methotrexate dosage · Alendronate dosage · Fluconazole dosage · Acetaminophen dosage · Diphenhydramine dosage · Naproxen dosage · Aspirin dosage · Cetirizine dosage · Dimenhydrinate dosage · Famotidine dosage.
Doses are transcribed from the FDA-approved label and are general reference information, not medical advice or a personal dose. Only a prescriber can set or change your dose. If you think you took too much, contact Poison Control (1-800-222-1222) or 911.